- Home
- SRPT vs ZLAB Comparison
SRPT vs ZLAB Comparison
Compare SRPT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | ZLAB |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SRPT | ZLAB |
|---|---|---|
| Price | $21.14 | $17.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 6 |
| Target Price | $26.23 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 3.3M | 1.0M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,413,715,000.00 | $441,629,000.00 |
| Revenue This Year | $13.83 | $30.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.15 | 24.14 |
| 52 Week Low | $10.42 | $16.82 |
| 52 Week High | $129.84 | $44.34 |
Technical Indicators
Market Signals| Indicator | SRPT | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 30.24 |
| Support Level | $20.14 | $16.82 |
| Resistance Level | $22.97 | $18.29 |
| Average True Range (ATR) | 1.25 | 0.60 |
| MACD | -0.07 | 0.18 |
| Stochastic Oscillator | 53.22 | 29.56 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.